- Home
- NBY
as 04-24-2025 4:00pm EST
Stocks
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 3.4M | IPO Year: | 2007 |
| Target Price: | $0.85 | AVG Volume (30 days): | 69.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $9.10 | Next Earning Date: | 05-08-2025 |
| Revenue: | $9,781,000 | Revenue Growth: | -6.45% |
| Revenue Growth (this year): | 23.91% | Revenue Growth (next year): | 32.05% |
Stock Insider Trading Activity of NovaBay Pharmaceuticals Inc. (NBY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| POPLAR POINT CAPITAL PARTNERS LP | NBY | 10% Owner | Apr 2 '25 | Buy | $0.53 | 28,731 | $15,966.98 | 1,015,462 | |
| POPLAR POINT CAPITAL PARTNERS LP | NBY | 10% Owner | Mar 18 '25 | Buy | $0.61 | 49,927 | $30,717.93 | 1,015,462 | |
| POPLAR POINT CAPITAL PARTNERS LP | NBY | 10% Owner | Mar 10 '25 | Buy | $0.61 | 64,175 | $39,503.18 | 1,015,462 | |
| POPLAR POINT CAPITAL PARTNERS LP | NBY | 10% Owner | Feb 3 '25 | Buy | $0.64 | 84,487 | $55,526.60 | 1,015,462 | |
| POPLAR POINT CAPITAL PARTNERS LP | NBY | 10% Owner | Jan 27 '25 | Buy | $0.67 | 102,388 | $67,700.16 | 1,015,462 |
Latest NovaBay Pharmaceuticals Inc. News
NBY Breaking Stock News: Dive into NBY Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
Business Wire
3 months ago
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
Zacks
4 months ago
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
Business Wire
4 months ago
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
Business Wire
5 months ago
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
Business Wire
5 months ago
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Business Wire
5 months ago
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Business Wire
6 months ago
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
Compare NBY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBY NovaBay Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.